Merck Stock Surges on Promising Cancer Vaccine Results

Merck & Company's stock has surged by 12.19% in the past week as investors react to promising data from its oncology partnership with Moderna.

The catalyst for this increase was the release of Phase 3 results from a personalized mRNA melanoma vaccine, Intismeran autogene, which is being co-developed with Moderna and used in combination with Merck's immunotherapy Keytruda.

In high-risk melanoma patients, the combo delivered a statistically significant improvement in recurrence-free survival compared with Keytruda alone.

Analysts have described this data as a 'watershed moment' for Moderna, underlining the strategic value of Merck's long-running bet on immuno-oncology and mRNA technology.